Ohio State University Launches First National Program to Train Providers on Psychedelic Crisis Response
Psychedelic use is rising across America. Ohio State University wants first responders ready for what comes next.
The university announced a groundbreaking program this month. It will train 127,000 providers to handle adverse reactions to hallucinogens. The initiative marks the first of its kind in the nation.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
| Key Takeaways | Details |
|---|---|
| Program Scope | Training 127,000 providers including behavioral health workers, public safety officers, and social workers |
| Core Focus | Teaching first responders to recognize and treat psychedelic crisis situations |
| National Significance | First program of its kind in the United States |
| Complementary Efforts | OSU launched a Certificate in Interdisciplinary Psychedelic Studies |
| Cost | Free training for all participants |
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
The Problem with Rising Use
Hallucinogen use jumped more than a percentage point between 2021 and 2025. More people experimenting means more people showing up in emergency departments.
“More and more folks are showing up because they’re having things like panic or anxiety,” said Alan Davis. He directs Ohio State’s Center for Psychedelic Drug Research and Education.
Why Traditional Approaches Fall Short
Treating someone on psychedelics differs vastly from alcohol or cannabis cases. Providers often mistake a difficult trip for a psychotic episode. This misdiagnosis can worsen outcomes.
People may see or hear things that aren’t real. Standard interventions can escalate their distress. The goal shifts to creating calm rather than immediate containment.
RELATED: How Psychedelics Are Changing the Way We Treat Mental Health
What the Training Covers
Participants will learn to identify psychedelic substances and their effects. They’ll study potential complications and drug interactions. Case studies will guide them through crisis scenarios.
The free program emphasizes harm reduction. Davis stresses accessible education. Psilocybin remains illegal in Ohio and holds Schedule 1 status federally. Yet mainstream use continues growing.
“Because they’re illegal, we don’t have a lot of education out there for folks,” Davis explained. “We want people to be equipped with knowledge so that if they choose to do this, they can do it as safely as possible.”
This program represents a pragmatic shift in public health strategy. Ohio positions itself at the forefront of psychedelic research while addressing immediate community needs.
